Background And Objectives: Serological screening for Chagas' disease in the blood banks of South America is carried out by using two different assays that generally show a high number of inconclusive results. To establish a combination of two tests that can minimize the number of inconclusive results, we compared a recombinant enzyme-linked immunosorbent assay (ELISA) with two conventional tests.
Materials And Methods: Serum samples from chagasic patients (n = 112), from non-chagasic individuals (n = 143) and from patients with other diseases (n = 32) were tested using three assays: recombinant ELISA (Rec-ELISA); conventional ELISA (Con-ELISA); and the indirect haemagglutination (IHA) test.
Results: When we evaluated the data by matching the Rec-ELISA and the IHA test, 52 inconclusive results were obtained. When Rec-ELISA and Con-ELISA were matched, only four inconclusive results were observed.
Conclusions: Our investigation indicates that the use of two ELISAs with different antigen preparations provides an effective test combination for blood bank screening of Chagas' disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1046/j.1423-0410.2003.00340.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic value of Chagas heart disease on short- and long-term clinical outcomes in patients hospitalized for COVID-19.
Trans R Soc Trop Med Hyg
January 2025
Department of Cardiology and Cardiovascular Surgery, Faculdade de Medicina de São José do Rio Preto, SP, 15090-000, Brazil.
Background: Immunological similarities led us to explore potential interactions between Chagas heart disease (CHD) and coronavirus disease 2019 (COVID-19). We evaluated CHD's impact on the short- and long-term clinical courses of COVID-19 patients.
Methods: The CHD group comprised consecutive hospitalized patients (March 2020-March 2022), while the controls were selected through genetic matching based on COVID complications predictors.
Editorial: Recent advances in the prevention, diagnosis and treatment of Chagas disease.
Front Microbiol
December 2024
National Center for Structural Biology and Bioimaging, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
A scoping review of the motor impairments in autism spectrum disorder.
Neurosci Biobehav Rev
January 2025
Laboratory of Cognitive Neurophysiology (LabNeuro), Institute of Biological Sciences, Department of Biophysics and Physiology, Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil; Post-Graduation Program in Rehabilitation Sciences and Physical-Functional Performance, Federal University of Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil. Electronic address:
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder mainly defined by impairments in communication and socialization. Although motor symptoms are not typically considered central to the disease, their high frequency and early onset have been recurrently reported in the literature. Therefore, this scoping review provides a broad description of these motor impairments across all ages, as well as a discussion of their relevance and relation to other clinical aspects of ASD.
View Article and Find Full Text PDFCationic and anionic PLGA-cholesterol hybrid nanoparticles as promising platforms to enhance the trypanocidal efficacy of benznidazole and drug delivery in Trypanosoma cruzi-infected cells.
Biomed Pharmacother
January 2025
Laboratory of Pharmaceutical Technology and Biotechnology, Department of Pharmacy, Federal University of Rio Grande do Norte-UFRN, Natal, RN, Brazil. Electronic address:
Chagas disease is a neglected tropical disease caused by the protozoan Trypanosoma cruzi, remains a significant global health challenge. Currently, benznidazole (BNZ) is the primary treatment in many countries. However, this drug is limited by low bioavailability, significant host toxicity, and reduced efficacy in chronic disease phase.
View Article and Find Full Text PDFIn vitro assays identified thiohydantoins with anti-trypanosomatid activity and molecular modelling studies indicated possible selective CYP51 inhibition.
Sci Rep
January 2025
Departamento de Química, Centro de Ciências Exatas, Universidade Estadual de Londrina, Londrina, PR, Brasil.
This work investigates the anti-trypanosomal activities of ten thiohydantoin derivatives against the parasite Trypanosoma cruzi. Compounds with aliphatic chains (THD1, THD3, and THD5) exhibited the most promising IC against the epimastigote form of T. cruzi.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!